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Abstract 
Background: Relapsing-remitting multiple sclerosis (RRMS) is an incurable disease 
characterised by relapses (periods of function loss) followed by full or partial recovery, and 
potential permanent disability over time. Many disease modifying treatments (DMTs) exist 
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which help reduce relapses and slow disease progression. Most are contraindicated during 
conception/pregnancy, and some require a discontinuation period before trying to conceive. 
Although around three-quarters of people with RRMS are women, there is limited knowledge 
about how reproductive issues impact DMT preference. 
Aim: To measure the preferences for DMTs of women with RRMS who are considering 
pregnancy. 
Design: An online discrete choice experiment (DCE). 
Methods: Participants chose between two hypothetical DMTs characterised by a set of 
attributes, then they indicated if they preferred their choice to no treatment. Attributes were 
identified from interviews and focus groups with people with RRMS and MS professionals, 
and literature reviews, and included probability of problems with pregnancy, discontinuation 
of DMTs, and breastfeeding safety. In each DCE task participants were asked to imagine 
making decisions in three scenarios: now; when trying to conceive; and when pregnant. 
Analysis: Two mixed logit models were estimated, one to assess the statistical significance 
between scenarios and one in maximum acceptable risk space to allow comparison of the 
magnitudes of parameters between scenarios. 
Sample: Women with RRMS who were considering having a child in future, recruited from a 
UK MS patient Register. 
Results: N=60 respondents completed the survey. Participants preferred no treatment in 12.6% 
of choices in the now scenario, rising significantly to 37.6% in the trying-to-conceive and 
60.3% in the pregnant scenarios (Kruskal-Wallis p<.001). This pattern corresponds with 
results from models, which included a no treatment alternative specific constant (ASC) 
capturing differences between taking and not taking a DMT not specified by the attributes. 
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The ASC was lower in the trying to conceive than in the now scenario and lower still in the 
pregnant scenario, indicating an intrinsic preference for no treatment.   Participants also 
placed relatively less preference on reducing relapses and avoiding disease progression in the 
trying-to-conceive and pregnant scenarios compared to a lower risk of problems with 
pregnancy. In the trying-to-conceive scenario, participants’ preference for treatments with 
shorter washout periods increased. 
Conclusion: Women with RRMS considering having a child prefer DMTs with more 
favourable reproduction related attributes, even when not trying to conceive. Reproductive 
issues also influence preferences for DMT attributes not directly related to pregnancy, with 
preferences dependent on the life circumstances in which choices were made. The DCE’s 
design highlights the benefits of considering the scenario in which participants make choices, 
as they may change over time. 
Key points 
• We used a discrete choice experiment (DCE) to study the preferences for disease 
modifying treatments (DMTs) of women with relapsing-remitting multiple sclerosis 
who may consider having a child  
• Using an innovative design we elicited preferences in three scenarios: now, when 
trying to conceive, and when pregnant. 
• In the trying-to-conceive and pregnant scenarios, participants were more likely to 
choose no treatment, with participants having both a greater intrinsic preference for 
no treatment and also considering the benefits of treatment relatively less important 
compared to potential problems with pregnancy. 
1. Introduction 
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Multiple sclerosis (MS) is an incurable inflammatory and degenerative disease of the central 
nervous system [1-3] which affects an estimated 150 people in every 100,000 [4]. Around 75% 
of people with MS are women [5] and the disease typically first appears in younger people, 
with the mean age of diagnosis at around 30 years. [6, 7]. The most common form of the 
disease at diagnosis is relapsing-remitting multiple sclerosis (RRMS), which affects around 
85% of patients [1]. RRMS is characterised by temporary episodes of loss of function termed 
relapses, followed by full or partial recovery, with a wide range of symptoms including loss 
of vision, mobility problems, pain, fatigue and cognitive impairment [1]. 
No cure exists for MS, but there are many disease modifying treatments (DMTs) available for 
RRMS which can reduce the frequency of relapses and lower the risk of accumulating 
disability [8, 9]. Individuals’ choices as to which DMT to take, or whether to take a DMT at 
all, can be complex, as treatments vary in efficacy and side effect profile. They also vary in 
mode of administration, with tablet, self-injection and infusion based treatments all available 
[10, 11].  
Reproductive choices have an impact on the decision of which (if any) DMT to take (and vice 
versa). [12-14]. Although some DMTs (e.g. glatiramer acetate) are safe to be taken in 
pregnancy [15] others are contraindicated due to problems with conception, pregnancy and/or 
breastfeeding and there is a lack of evidence for some DMTs as to whether they are safe 
during conception/pregnancy or not [16-19]. Risks associated with some DMTs include 
increased risks of miscarriage, premature birth, low birth weight and congenital anomalies. 
Further complicating the decision-making context is the fact that pregnancy and childbirth 
can affect the course of women’s MS. For example, some evidence suggests women may 
experience a reduction in their relapse-rate when pregnant, but an increased risk of relapse in 
the post-partum period [20-23], though more recent evidence does not support the hypothesis 
of an increase in disease activity post-partum Finally, there is evidence that some women 
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with RRMS have concerns about the impact of their disease on their ability to care for a new-
born [24, 25], which has the potential to influence preferences for treatment. Yet, the 
influence of reproductive issues on women’s preferences is still not well understood. 
Clinician advice around reproduction and DMTs may vary due to the lack of an evidence-
base on treatment safety particularly for newer treatments [26-29]. A better understanding of 
how reproduction influences women’s preferences for DMTs could help to develop more 
effective strategies to support their decision making process.  
This study uses a discrete choice experiment (DCE) to investigate the impact reproductive 
issues have on women’s DMT preferences [30-32]. It is part of a wider project entitled 
Considering RIsk and benefits in Multiple Sclerosis treatment selection (CRIMSON), which 
examined people with RRMS’ preferences for and attitudes towards DMTs using a variety of 
approaches. The project included qualitative studies [33], literature reviews [12, 32] and two 
linked DCEs, one without reproduction related attributes, and the current study which 
specifically examined reproduction. The evidence from these studies was then used in the 
development of a patient decision aid [34] for people with RRMS making DMT choices [35]. 
Previous DCE studies have explored people’s preferences for MS treatments [32, 36-38], but 
only one has explored how reproductive issues impact treatment preferences [39], and 
reproduction has been highlighted as a neglected area in the DCE literature in MS [32]. 
This study’s primary aim was to examine reproduction related attributes of DMTs in detail. 
We recruited women considering having a child in future, for whom reproductive issues were  
assumed to be most relevant [12]. The study also aimed to capture the dynamic nature of 
DMT decision-making, and how reproduction influences choices at different points in 
people’s lives. Participants were asked to imagine making their choices between DMTs in 
three different scenarios: now, when trying to conceive, and when pregnant. An additional 
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aim of the study was to assess the feasibility of using such a design, and whether participants 
would make systematically different choices in different scenarios. 
2. Methods 
Sample 
The target population was women with RRMS (wwRRMS) who indicated they intended to 
have children in future. Recruitment was done online using the MS Register 
(ukmsregister.org), a large UK panel of people with MS who are regularly invited to 
participate in research surveys. The MS Register has over 15,000 people registered, although 
only a fraction had consented to receive invitations from third parties to take part in research 
such as this study at the time of recruitment. No payment is given for participation. 
Materials 
In line with good practice [40, 41], the survey instrument was developed using a qualitative 
process and following established guidelines [42-44]. This involved interviews (N=30) with 
people with RRMS [33] and three focus groups (N=17) with people with RRMS, neurologists 
and MS nurses to generate candidate attributes. 
A finding which emerged from the qualitative data collection was that reproduction-related 
aspects of DMTs were important factors in many participants’ decision-making. 
Reproductive issues were also identified as a neglected topic in DCEs in MS [12, 32]. 
However, including reproduction-specific attributes in a DCE targeted at all people with 
RRMS would not give an appropriate measure of their importance, since they would only be 
relevant to a subset of the target population. The original study design of a single DCE was 
hence changed in response to the emerging qualitative findings. This resulted in two DCEs, 
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one without reproduction-specific attributes with a target population of all people with RRMS, 
and one with wwRRMS who were considering having a child in the future. 
A ranking exercise was conducted with four workshops (N=33) with people with RRMS to 
prioritise which attributes to include. In order not to overburden participants, two attributes 
included in the general DCE were excluded from the reproduction DCE. Participants were 
instructed to assume that for the excluded attributes to all DMTs in the reproduction DCE had 
the same level. 14  A draft survey was refined in an iterative process of 28 think-aloud 
interviews with people with RRMS. This process addressed whether the survey was 
understandable, whether attributes and levels were interpreted as intended, whether the tasks 
presented an acceptable burden, and general presentation and usability issues. Probabilistic 
risk information was presented using simple numerical formats accompanied by visual aids 
(see Figure 1), following evidence-based principles to facilitate understanding [45, 46]. The 
final list of attributes and levels for the reproduction DCE is given in Table 1, and the 
attributes and levels included only in the general DCE are given in the supplementary online 
material, as well as a copy of the survey which shows how attributes and levels were 
explained to participants. 
The reproduction DCE had a dual response, multiple scenario design. Participants first chose 
which of two DMTs they preferred, and then indicated whether they preferred it to no 
treatment. They were also asked to imagine making decisions in three scenarios. First they 
were asked to imagine making their choice now, then making their choice when trying to 
conceive, and finally making their choice when pregnant. Figure 1 gives screenshots of a 
 
14 The two attributes were relapse severity and chance of additional long-term and/or life-threatening 
medical condition over 4 years. 
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sample question, and Figure 2 shows how each individual sub-question was presented 
sequentially. 
A Bayesian D-efficient statistical design for the reproduction DCE was created using Ngene15 
with a main effects model with zero priors. Choices where one treatment was superior on all 
levels apart from mode of administration were excluded. The final design had 10 blocks of 
five questions each. The NGene code is available as online supplementary material. The 
order attributes were presented in was randomised between participants, but consistent across 
questions for a given participant, and pregnancy specific attributes were grouped together.  
Procedure 
Participants completed a DCE without reproduction related attributes, then a short series of 
questions about themselves, their RRMS and treatment history. Both male and female 
participants were asked “Are you or your partner thinking about having a child, either soon or 
in the next few years? (yes/no).” If they responded yes, they were asked to complete the 
reproduction DCE. Male participants completed a reproduction DCE without the attribute 
Safe to breastfeed or the pregnant choice scenario. These data were not analysed due to a 
small sample size (N=7). Participants were asked if they were currently trying to conceive or 
currently pregnant, with the aim of incorporating this information into the modelling (see 
below). 
Analysis 
The fraction of times each participant chose no treatment as their most preferred option in 
each scenario was calculated. The statistical significance of differences between scenarios 
was assessed using a Kruskal-Wallis test. 
 
15ChoiceMetrics 
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The utility individual 𝑖 receives from choosing treatment 𝑗 over the alternative treatment in 
choice situation 𝑘 was assumed to take the form 
𝑢𝑖𝑗𝑘 = 𝛽𝑖𝑘𝑥𝑖𝑗𝑘 + 𝜀𝑖𝑗𝑘 . 
Here 𝑥𝑖𝑗𝑘 is a vector indicating the levels of each attribute for treatment 𝑗 in situation 𝑘, 𝛽𝑖𝑘  is 
a vector describing 𝑖 ’s preferences and 𝜀𝑖𝑗𝑘  is an independent and identically distributed 
extreme valued error term. The utility that 𝑖  receives from choosing no treatment over 
treatment is assumed to take the same form as the above equation, with the addition of an 
alternative specific constant (ASC). The ‘no treatment’ ASC is interpreted as capturing all 
aspects of taking no treatment compared to taking a DMT not explicitly captured by the 
attributes. For example, it might include an intrinsic desire for treatment due to being on a 
DMT giving a sense of control over an individual’s disease, over and above any benefits it 
brings [12]. Alternatively, it might include an intrinsic preference for avoiding treatment to 
prevent it affecting an unborn child, over and above any explicitly stated risk. 
The probability of choosing treatment 𝑗 ∈ {1,2} over treatment 𝑙 ≠ 𝑗 in the first stage and then 
preferring 𝑛𝜖{𝑗, 𝑛𝑜 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡} in the second stage is 







where 𝑉𝑗 = 𝛽𝑖𝑘𝑥𝑖𝑗𝑘  is the deterministic component of utility. 
A mixed logit model was used, with coefficients, including the no treatment ASC, assumed to 
be normally distributed, i.e. for coefficient 𝑚 , 𝛽𝑖𝑚𝑘 𝑁(𝜇𝑚𝑘, 𝜎𝑚
2 ) . Both normally and log-
normally distributed parameters are common assumptions [47]. The former was chosen as 
normal distributions allow the possibility of a parameter having no influence of average 
The impact of reproductive issues on preferences of women with relapsing MS for DMTs 
10 
 
preferences, which was considered a plausible possibility. The influence of scenarios is 







where the dummy variables 𝑡𝑘
𝑐𝑜𝑛𝑐𝑒𝑖𝑣𝑒  and  𝑡𝑘
𝑝𝑟𝑒𝑔𝑛𝑎𝑛𝑡
 take the value 1 either if choice situation  
𝑘 is in the trying-to-conceive/pregnant scenario or if 𝑖 indicated she was currently trying to 
conceive/pregnant and take the value 0 otherwise. The term 𝜇𝑚
𝑛𝑜𝑤 gives the parameter mean in 
the now scenario, and the terms 𝜇𝑚
𝑐𝑜𝑛𝑐𝑒𝑖𝑣𝑒  and 𝜇𝑚
𝑝𝑟𝑒𝑔𝑛𝑎𝑛𝑡
 show how the parameter mean 
changes in the trying-to-conceive and pregnant scenarios. The standard deviation of 
parameters is assumed to be the same in all scenarios. For participants who reported they 
were trying to conceive/pregnant, preferences were assumed to be identical in the 
conceive/pregnant scenario and the now scenario. 
The model above was designed to maximise the chances of seeing if differences in 
preferences across scenarios were statistically significant. However, comparing the 
magnitudes of model parameters in different scenarios may result in problems, as changes 
may be due to a shift in response scale rather than different preferences [48]. The influence of 
the response scale can be eliminated by choosing one parameter as a numeraire, and the 
magnitude of other parameters compared to it. Here, problems with pregnancy16 was chosen 
as the numeraire, so that other attributes were expressed in terms of the maximum acceptable 
risk (MAR) of problems with pregnancy. 
Two models were estimated. One was designed to maximise the chances of finding 
statistically significant differences between scenarios, and the other was designed to allow 
 
16 Participants were told that risks could include low birth weight, premature birth or miscarriage, with 
the levels of risk presented to participants of similar magnitude to those observed in the literature [49, 
50]. 
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comparison of the magnitudes of participants’ preferences between scenarios. The utility to 
person 𝑖 of choosing treatment 𝑗 in choice situation 𝑘 was modelled as 
𝑢𝑖𝑗𝑘 = 𝜶𝑖𝑘𝒙𝑖𝑗𝑘 + 𝜆𝑖𝑟𝑗𝑘 + 𝜂𝑖𝑗𝑘  
where 𝑟𝑗𝑘 is the risk of problems with pregnancy for 𝑗, 𝜆𝑖 represents 𝑖’s preferences for risk of 
problems with pregnancy, 𝜶𝑖𝑘 is a vector representing her preferences for other attributes and 
𝜂𝑖𝑗𝑘 is an error term. This may be rearranged to give 




⁄  gives 𝑖’s MAR of problems with pregnancy to receive an extra unit of 
other attributes. This formulation is analogous to models estimated in willingness-to-pay 
space [51, 52] and has the advantage that a distribution can be directly assumed for MAR. 
Calculating MAR from the results of the previous model would require taking the ratio of 
two normal distributions, which has undefined moments. 




𝑠𝜖{𝑛𝑜𝑤, 𝑐𝑜𝑛𝑐𝑒𝑖𝑣𝑒, 𝑝𝑟𝑒𝑔𝑛𝑎𝑛𝑡} , so in contrast to the previous model, coefficients in the 
conceive and pregnant scenarios were not interaction terms. The parameter 𝜆𝑖 was modelled 
as following a log-normal distribution and the 𝛾𝑖
𝑠 ’s were modelled as following normal 
distributions. Means were allowed to vary over scenarios (with the exception of 𝜆𝑖 to ensure 
the model was identified) but variances were not, as it was not possible to robustly estimate a 
model without this restriction. 
Models were estimated using the Apollo choice modelling package for R [53]. Statistical 
significance of model coefficients was assessed using t-tests and was judged at the 5% level. 
3. Results 
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Invitations to take part were sent to approximately 1,500 people. A total of 675 out of 845 
(80%) participants completing the survey reported being female. Of these, 61 indicated they 
(or their partner) were considering having a child, either in the present or future. A total of 60 
completed the reproduction DCE. Of these, 14 were currently trying to conceive, and nobody 
reported currently being pregnant. Table 2 summarises participants’ demographics and their 
experiences with DMTs. 
Most participants had been living with MS for some years (median four years) and almost 90% 
had experience of taking a DMT at some point. As few participants were treatment naïve, the 
DCE tasks of choosing between DMTs were relevant to them. Around a quarter of 
participants reported having a child/children in their household, so many will also have had 
previous experience of pregnancy. 
In the now scenario, no treatment was chosen 12.6% of the time, which rose to 37.6% in the 
trying to conceive scenario and 60.3% in the pregnant scenario.17 A Kruskal-Wallis test 
confirmed the differences across scenarios were statistically significant (p<.001). 
The results of model estimation are given in Table 3. In the now scenario, participants were 
significantly more likely to choose treatments giving fewer relapses, a lower probability of 
progression and without severe side effects. Daily pills were the most preferred mode of 
administration, although the difference in preference between two infusions a year apart and a 
daily pill was not significant. Injection and monthly infusions were significantly less popular 
than pills. Participants preferred treatments with a lower chance of problems with pregnancy. 
Although the sign of the parameter means indicate that participants preferred treatments with 
shorter washout times (i.e. with a shorter time to leave their system once they stop treatment) 
 
17 Participants who were currently trying to conceive making choices in the now scenario were 
modelled as being in the trying to conceive scenario. 
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and which were safe to breastfeed on, neither was statistically significant. They were also 
significantly more likely to choose treatments with a lower chance of problems with 
pregnancy and which were safe to breastfeed on. The mean no treatment ASC (which 
captured preferences for taking no treatment not explicitly captured by the attributes) was 
negative, indicating a preference for taking a DMT over and above their properties captured 
by the attributes, but not significant. 
The coefficients for the trying-to-conceive and pregnant scenarios are interaction terms, and 
represent changes in preferences relative to the now scenario. There were seven significant 
interactions for the trying-to-conceive scenario. For number of relapses, probability of 
progression, moderate and severe side effects, injection and monthly infusions, the 
interactions reduced the absolute magnitude of the parameter, indicating a lesser importance 
in decision-making. The interaction for washout period increased the absolute magnitude of 
the parameter, indicating greater importance in decision-making compared to the now 
scenario (Table 3). 
There were six significant interactions in the pregnant scenario. Five reduced the absolute 
magnitude of the parameter, meaning lower importance in decision-making: number of 
relapses, chance of progression, moderate and severe side effects, and monthly infusions. The 
interaction for the no treatment ASC was positive, and sufficiently large to increase the 
absolute magnitude of the parameter. This implies that the differences between no treatment 
and treatment not explicitly captured by the attributes had greater importance in decision-
making compared to the now scenario, and that in the pregnant scenario participants preferred 
no treatment. 
Table 4 gives the results of the model in maximum acceptable risk (MAR) space. To aid 
comparison between scenarios, the results are illustrated in Figure 3. Unlike Table 3, the 
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figure shows absolute preferences for the trying-to-conceive and pregnant scenarios, not 
changes relative to the now scenario, and preferences in different scenarios may be compared 
as they are measured in terms of MAR of problems with pregnancy. MAR of problems with 
pregnancy was lower in the trying-to-conceive and pregnant scenarios than in the now 
scenario for reducing the number of relapses, lowering the chance of progression, and 
avoiding moderate and severe side effects. There was also lower MAR of problems with 
pregnancy to obtain a daily pill rather than an injection or a monthly infusion. There was little 
difference in MAR for the above attributes between the trying-to-conceive and pregnant 
scenarios. MAR was similar across scenarios for a shorter washout period and having a 
treatment which is safe to breastfeed on. The greatest changes across scenarios were seen for 
the no treatment ASC. Participants had a MAR of problems with pregnancy of 33.7% in the 
now scenario, which reduced to 19.0% in the trying to conceive scenario and -14.7% in the 
pregnant scenario, the negative sign implying a preference for no treatment over treatment. 
4. Discussion 
Considering the now scenario and the non-pregnancy-related attributes, results are as 
expected, and in line with previous DCE findings (e.g. [37, 38]). Participants were more 
likely to choose treatments which reduced the number of relapses experienced, and the 
probability of future loss of function, and with less severe side effects. As has previously 
been observed [54-57], participants preferred a daily pill over other modes of administration. 
The daily pill may fit better into participants’ daily lives, despite its increased frequency 
compared to other modes of administration. This notion is in accordance with findings from 
the qualitative data gathered during attribute development suggesting that pills were easier to 
incorporate into a normal routine, for example taking them alongside vitamins [58]. The 
similarities between previous studies which recruited from the population of all people with 
RRMS and this study which elicited the views of wwRRMS considering pregnancy suggests 
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there are few fundamental differences between the two populations in attitudes towards non-
pregnancy-specific attributes of DMTs.  
In the now scenario, even when not actively trying to conceive, risk of problems with 
pregnancy influenced participants’ choices. Two possible explanations of this finding, are: 
first, participants may have recognised the possibility of an unplanned pregnancy, given that 
the rate of unplanned pregnancies has been estimated to be as high as 50% [59], leading them 
to choose pregnancy-friendly treatments in case of this eventuality. Corroboration for this 
was found in the qualitative attribute development work, where some interview participants 
identified unplanned pregnancy as a worry about taking DMTs [33, 58].  Alternatively, 
participants may have wished to avoid the disruption associated with switching or stopping 
treatment and choose a DMT now that they would be happy to continue taking when trying to 
conceive or pregnant. Both explanations have the underlying rationale of the safety of a 
potential foetus, and are not mutually exclusive. 
Participants’ preferences varied according to scenario type. There was a dramatic increase in 
the number of times no treatment was the most preferred option, from just over 10% in the 
now scenario, to just under 40% when trying to conceive, to around 60% when pregnant. A 
large driver of this change was interactions with the no treatment ASC, which had the largest 
relative magnitude in both the trying-to-conceive and pregnant scenarios. The ASC captured 
general preferences for no treatment over any DMT not captured by preferences for the 
attributes, and so the interactions can be interpreted as participants being more reluctant to 
take any sort of treatment while pregnant, irrespective of the particular properties of the 
treatment. The above results are in line with previous findings  that many women cease 
taking DMTs when trying to conceive or pregnant, with the aim of resuming treatment at 
some point after childbirth. 
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The shift in preferences towards no treatment was also driven by relatively lower importance 
of non-reproduction specific attributes of treatments. In both the trying-to-conceive and 
pregnant scenarios, number of relapses, chance of future progression, side effect severity and 
having a preferred mode of administration became relatively less important. This may 
indicate that when participants began actively trying to conceive, they would change the 
trade-offs they would make between their own current/future health and risks to a foetus. It 
also suggests that participants were more willing in those scenarios to take treatments which 
are less convenient and more disruptive to their lifestyle as long as they experience a safer 
pregnancy. However, these trade-offs appear to be stable between the trying-to-conceive and 
pregnant scenarios. 
In Table 3 the interactions for chance of problems with pregnancy were insignificant in both 
the trying to conceive and pregnant scenarios. However, Figure 3 reveals that what 
individuals considered an acceptable risk of problems with pregnancy for beneficial attributes 
of treatments changes across scenarios, in line with the patterns discussed above. 
The term problems with pregnancy encompasses several conditions with varying severity, 
such as low birth weight and congenital abnormalities. Different participants may hence have 
had different perceptions of how severe problems may be. A single attribute was used partly 
to ensure the number of attributes was not so large as to overburden participants, and partly 
as in pre-testing, participants showed an aversion to terms such as congenital abnormalities. 
Future research could elicit more details about preferences and trade-offs between specific 
risks of DMTs. 
Participants had similar relative preferences for different modes of administration across all 
scenarios. Yet Figure 3 shows that the maximum acceptable risks (MARs) of problems with 
pregnancy were reduced by similar amounts in the trying-to-conceive and pregnant scenarios. 
The impact of reproductive issues on preferences of women with relapsing MS for DMTs 
17 
 
This may suggest that participants were more willing in those scenarios to take treatments 
which are less convenient and more disruptive to their lifestyle as long as they experience a 
safer pregnancy. 
 The results for the washout period can also be interpreted in line with a behavioural pattern 
of not wanting to take a DMT when pregnant: Participants were most likely to choose 
treatments with shorter washout periods in the trying-to-conceive scenario, which could 
indicate that if they were willing to take a DMT in this period, they would place a premium 
on being able to stop as soon as possible when they become pregnant. 
This study has some innovative features. It was the first stated preference study to examine 
reproduction-related attributes of DMTs in detail. It was also the first to focus on wwRRMS 
who may consider having a child, the population for whom reproductive issues are most 
pertinent.  
Another innovative feature of the study is that it reflected the dynamic nature of DMT 
decision-making, especially when considering pregnancy, by asking participants to imagine 
completing the DCE tasks in multiple scenarios. The feasibility of such a design has been 
demonstrated here: results were logical, and in line with expectations and previous results. 
Participants responded to the different scenarios, changing their behaviour both in regard to 
the relative importance of DMT attributes and whether to take a DMT or not.  
This study also has limitations. Scenarios were presented in the same order in each task (i.e., 
now, trying to conceive, pregnant). This design was chosen based on pre-testing, which found 
difficulties in communicating the concept of the task to participants. Presenting the scenarios 
in their logical order was important to make the tasks understandable to participants. 
However, this set order implies that order effects may have affected results to some extent. 
Future methodological work could usefully investigate the trade-offs between avoiding 
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possible order effects by randomising the order of scenarios and the increased complexity of 
the tasks for participants. 
Choices in the trying-to-conceive and pregnant scenarios were (for the majority of 
participants) being made for the future. There is a large body of evidence that individuals’ 
preferences can be time-inconsistent [58-60], and that individuals are generally poor at 
predicting what their experiences of future health states will be [61]. The current study 
measures people’s intentions as to what they will choose in the future, which may not 
correspond to their actual decisions when the time comes. While this is not necessarily a 
limitation in itself, as studying individuals’ intentions is still important and relevant, there 
may be a gap between intention and action. 
The sample size was small, although many DCEs have smaller sample sizes (e.g. [60]). 
Relatively few questions were asked due to the necessity of minimising respondent burden 
after already having answered several DCE questions. This means that there may be 
significant differences across scenarios which the DCE does not have sufficient power to 
detect. 
Another drawback to the low sample size was that it was difficult to explore heterogeneity. 
People were invited to complete the DCE if they reported that they were “considering having 
a child, either now or in the next few years”. Respondents who answered yes may have had 
various underlying reasons for doing so, ranging from currently trying to conceive to a 
general aspiration to have a child at some point in the future. The choice situations may hence 
have had differing relevance for participants. Although mixed logit models were used to 
account for heterogeneity, it is difficult to know why preferences differed across respondents. 
Future research could usefully explore potential sources of preference heterogeneity such as 
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previous experience of pregnancy, disease severity, or when an individual is planning to have 
a child in future. 
The small sample size indicates that the population of wwRRMS who are considering 
pregnancy is both relatively small and/or relatively difficult to engage. This does not imply, 
however, that issues relating to reproduction and DMTs are unimportant. Newly diagnosed 
wwRRMS are typically in their 20s, and the number for whom reproduction-related attributes 
of DMTs are relevant at any given time-point is lower than the number for whom they 
were/will be important at some point in their lives. Women who have not yet received an 
RRMS diagnosis, who have children and do not wish for more, who are no longer able to 
have children, or whose disease has become progressive, may not have found the DCE tasks 
meaningful to complete. Yet each group would find them meaningful at some time. 
Another weakness of this study was that it was performed as an addition to another DCE. A 
consequence of this is that although, in line with best practice [40, 41], qualitative methods 
were used to develop the survey instrument, some qualitative participants were not part of the 
target population of this DCE. It is also not possible to know how many were part of the 
target population, since the inclusion criteria for the DCE emerged relatively late in the study. 
On the other hand, that the relationship between reproduction and DMTs was an important, 
complex and time-sensitive topic to investigate was only revealed due to the extensive 
qualitative process used to develop the survey instrument, which could be regarded as a 
strength of the research project. In addition, as attributes and levels draw upon a large amount 
of qualitative data, there is a greater certainty than in many MS stated preference studies [32] 
that they were relevant to participants, were understandable, and were interpreted by 
participants as researchers intended. 
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The sample was self-selected from an online panel used to regularly completing surveys 
related to their disease, and may not be representative of the wider population of wwRRMS 
who were considering having a child in future. In addition, it is a limitation that some 
participants may not have found the reproduction attributes included relevant if, e.g., they 
were planning to adopt. 
There is opportunity for further work in this area. For example, future studies could explore 
heterogeneity of preferences, as decisions around reproduction are extremely personal. It 
would be instructive to investigate whether wwRRMS who are not currently considering 
having a child in future also consider reproduction-related factors in DMT decision-making. 
Given the difficulties of recruiting wwRRMS who were considering having a child, future 
studies could consider eliciting the preferences of wwRRMS who have previously had 
children. One drawback of that approach is that their preferences may be affected by recall 
bias [61]. Future studies may wish to study the preferences for men as well as women. 
Reproduction-related issues affect men’s DMT choices as well [62], and it is difficult to 
know to what extent the findings for women would be replicated with men. However, this 
project highlighted challenges to recruiting sufficient numbers of men. 
More generally, this study has demonstrated that reproduction-specific attributes of non-
reproduction treatments can have great importance to individuals. Many treatments for 
conditions other than RRMS, such as anti-depressants, seizure medication and steroids, can 
have risks for a foetus if taken during pregnancy [7, 63]. However, the impact of 
reproduction-related risks of treatments is often neglected in the DCE literature. Some 
research has been carried out into preferences for reproduction-specific treatments such as in 
vitro fertilisation [64-66], obstetric care [67],  perinatal depression [68], and smoking 
cessation during pregnancy [69]. However, these do not involve trade-offs between treatment 
benefits and reproduction risks. Several studies on prenatal testing [70-73] elicit trade-offs 
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between beneficial aspects of tests and risks to the foetus. Future DCEs looking at 
preferences for treatments with reproduction-related risks may wish to use an approach 
similar to the current study to examine the importance of such risks in patients’ decision-
making. 
5. Conclusion 
The results of this study indicate that wwRRMS considering having a child in future have 
preferences for reproduction-related attributes of DMTs, even when not actively trying to 
conceive. They also indicate that DMT decision-making in relation to reproduction is 
complex, and depends heavily on context. The findings from this study and the wider 
research project have been used as evidence to inform the content and structure of a patient 
decision aid for people making decisions about starting, switching and stopping taking DMTs 
for RRMS [35]. This study demonstrates that using multiple scenarios in a DCE is feasible 
and understandable by survey participants, and can improve the insight a study gives into 
complex decision-making situations in which participants’ preferences may change over time. 
Future DCEs may wish to consider adopting a similar approach. 
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Table 1: Attributes and levels 




Average number of 
relapses over 4 years 
1 relapse 2 relapses 3 relapses  4 relapses 
      




after 10 years 
650 out of 
1000 
(65%) 
700 out of 
1000 (70%) 
750 out of 
1000 
(75%) 
 800 out of 
1000 (80%) 
      
Typical side effects of 
treatment 













      




less than a 

























days at a 
hospital 
 
Chance of problems 
with pregnancy if 
taken during 
conception/pregnancy 
200 out of 
1000 
(20%) 
300 out of 
1000 (30%) 
400 out of 
1000 
(40%) 
 200 out of 
1000 (20%) 
      
Time for drug to 
leave your system 
after stopping 
treatment 
0 months 1 month 3 months   
      
Safe to breastfeed Yes No   Yes 
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Table 2: Demographic characteristics 
Variable N (%) 
Age   
    Mean (standard deviation) 34.4 (6.1) 
Highest education level obtained   
    Secondary school 6 (10) 
    Occupational qualification 9 (15) 
    Degree 16 (26.7) 
    Postgraduate qualification 21 (35) 
    Other 2 (3.3) 
    Missing 6 (10) 
Occupation    
    (Self-)employed 41 (68.3) 
    Unemployed 4 (6.7) 
    Voluntary work 1 (1.7) 
    Housework 2 (3.3) 
    Not working due to temporary/permanent disability 4 (6.7) 
    Other 1 (1.7) 
    Missing 6 (10) 
Are children under 18 living in participant’s  household? 16 (26.7) 
Current MS type    
    PPMS 2 (3.3) 
    RRMS 55 (91.7) 
    SPMS 1 (1.7) 
    Don't know 2 (3.3) 
MS type at diagnosis    
    RRMS 59 (98.3) 
    Don't know  1 (1.7) 
Years since MS symptoms first experienced   
    Median (range) 5.5 (1-22) 
    Missing 2 (3.3) 
Years since MS diagnosis   
    Median (range) 4 (1-22) 
    Missing 1 1.7 
DMT naive 7 (11.7) 
Currently taking DMT 47 (78.3) 
For non-DMT naive participants, number of DMTs experienced   
    Median (range) 2 (1-4) 
N 60  
Note. Italics indicate data from MS Register   
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Table 3: Model estimation results 
  Now Trying to conceive interaction Pregnant interaction 
  Mean s.d. Mean s.d. Mean s.d. 
Number of relapses  -1.08* 1.17* 0.877* 0.725 0.919* 0.328 
  (0.276) (0.284) (0.309) (0.483) (0.305) (0.360) 
% chance of progression -0.207* 0.107* 0.188* 0.231 0.199* 0.0817 
  (0.0516) (0.0521) (0.0428) (0.124) (0.0529) (0.0650) 
Side effects Mild Baseline      
 Moderate -0.981* 1.04* 1.30* 0.439 1.38* 0.414 
  (0.391) (0.412) (0.561) (0.604) (0.513) (0.533) 
 Severe -1.50* 1.81 1.88* 2.64 1.80* 0.476 
  (0.557) (1.31) (0.773) (1.52) (0.629) (1.34) 
Administration Pill Baseline      
 Injection -1.88* 1.35* 1.84* 1.26 1.38 1.29* 
  (0.746) (0.442) (0.790) (0.646) (0.822) (0.599) 
 Monthly 
IV 
-1.46* 1.09 2.46* 0.548 1.89* 0.199 
 (0.576) (0.603) (0.716) (1.17) (0.732) (0.804) 
 Yearly IV -0.817 2.22* 0.914 2.07 0.913 0.31 
  (0.632) (0.551) (0.689) (1.13) (0.688) (0.901) 
Washout period 
(months) 
 -0.339 0.588* -0.793* 0.57 -0.214 0.275 
 (0.201) (0.199) (0.299) (0.292) (0.223) (0.242) 
% chance problems with pregnancy -0.110* 0.148* -0.105 0.09 -0.0283 0.123* 
  (0.0240) (0.0462) (0.0644) (0.0523) (0.0324) (0.0508) 
Safe to breastfeed Yes Baseline      
 No -0.71 1.27* -0.0295 2.02* 0.0261 0.807 
  (0.400) (0.561) (0.526) (1.02) (0.461) (0.647) 
No treatment ASC  -1.15 1.91* 0.332 2.71* 3.74* 5.30* 
  (1.07) (0.885) (1.31) (1.01) (1.20) (1.05) 
Note. Standard errors in parentheses; * indicates significance at the 5% level; s.d. = standard deviation; 900 observations from 60 participants; 
log-likelihood = -758.81 
 




Table 4: Estimation results of model in maximum acceptable risk space 
  Now Trying to conceive Pregnant Standard deviation 
Number of relapses  13.1* 2.82* 4.89* 6.30* 
  (0.860) (0.281) (0.526) (0.493) 
% chance of progression  2.12* 0.408* 0.427* 1.39* 
  (0.0627) (0.0918) (0.113) (0.0719) 
Side effects Mild Baseline    
 Moderate 9.89* -1.37 2.59* 4.92* 
  (0.136) (0.873) (0.790) (1.27) 
 Severe 30.4* 14.3* 16.2* 19.4* 
  (3.39) (0.953) (2.64) (1.50) 
Administration Pill Baseline    
 Injection 19.1* 10.2* 10.7* -0.256 
  (3.80) (1.98) (1.40) (0.657) 
 Monthly IV 15.4* 1.89 -0.968 11.4* 
  (0.167) (2.65) (1.28) (0.100) 
 Yearly IV -1.87 0.732 0.359 11.4* 
  (3.02) (1.96) (2.07) (1.00) 
Washout period (months)  5.51* 6.53* 6.15* 5.71* 
  (0.109) (0.307) (0.240) (0.270) 
% chance problems with pregnancy -0.110*   1.68* 
  (0.139)   (0.138) 
Safe to breastfeed Yes Baseline    
 No 6.69* 7.08* 8.68* 1.16* 
  (0.366) (0.701) (2.32) (0.222) 
No treatment ASC  35.7* 19.0* -14.7* 29.5* 
  (4.15) (2.04) (0.203) (2.19) 
Note. Standard errors in parentheses; * indicates significance at the 5% level; s.d. = standard deviation; 900 observations from 60 participants; 
log-likelihood = -744.78 
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Figure 1: Example choice task 
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Figure 2: Illustration of how scenarios were presented sequentially. Each subfigure shows the additional task which was presented after 
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Figure 3: Maximum acceptable risks of problems with pregnancy for other attributes. Error bars show 95% confidence intervals. 
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